A VALIDATED RP-HPLC ASSAY METHOD FOR DETERMINATION OF GEMCITABINE LOADED NANOSIZED SOLID LIPID NANOPARTICLES
A novel reverse phase HPLC assay method has been developed and validated for the simultaneous determination of Gemcitabine Hydrochloride (dFdCH) along with solid lipid nanoparticles SLNs and conjugated with mannose to targeting the lungs for chemotherapy. Methanol was used as the extracting solvent for preparation of tissue sample. Methanol: Ammonium acetate buffer; 10:90 v/v (pH 5) was the mobile phase at flow rate 1.5 mL/min at pressure of 102/101 bars using Luna Phenomenex, C18 (4.6mmÃ—250 mm; 5 Âµm bead size) at wavelength 269 nm. The column oven temperature was optimized at 350C. The biodistribution studies were conducted to evaluate the target potential at the sites of interest in liver, spleen, lung and kidney respectively, the calibration curve was found to be linear over the concentration range of 100-5000 ng/mL(r2=0.9980, r2=0.9980, r2=0.9990, r2=1 respectively). Plain drug have greatest access to liver and secondarily to spleen and then kidney but on the contrary the concentration of drug was greatest in lung when treated with mannosylated SLNs, data suggested that the mannose attachment has provided the access for the drug in the lungs via the formulation in greater quantity than free drug due to interaction of mannose with mannose receptors present on lung macrophages. The developed method was validated in accordance to ICH guidelines.
Keywords: High Performance Liquid Chromatography, Mannosylated SLNs, Macrophage Mannose, Receptor (MMR), Lung Cancer, Gemcitabine Hydrochloride.
2. Williams DA, Lemke TL, Foyeâ€™s Principle of Medicinal Chemistry, fifth ed., 2002, 936.
3. Kleespies A, Jauch KW, Bruns CJ, Drug Resistance Updates 2006; 9:1â€“18.
4. Xu J, Zhou Y, Zhang J, Chen Y, Zhuang R, Liu T, Cai W, Clinica Chimica Acta 2012; 413:1284â€“1287.
5. Adachi S, Yasuda I, Kawaguchi J, Yamauchi Nakashima TM, Itani M, et al, Biochemical and Biophysical Research Communications 2011; 414:53â€“59.
6. Imen A, Amal K, Ines Z, Sameh EF, Fethi EM, Habib G, Respiratory Medicine, 2006; 100:1463â€“1465.
7. Pauwels B, Korst AEC, de Pooter CMJ, Lambrechts H.A.J., Pattyn G.G.O., Lardon F, Vermorken J.B., European Journal of Cancer 2003; 39:838â€“846
8. Medina SH, Md. E. H. El-Sayed Chem. Rev. 2009; 109:3141â€“3157.
9. Peterson J, Ebber A, Allikmaa V, Lopp M, Proc. Estonian Acad. Sci. Chem., 2001; 50(3):156â€“166.
10. Keith B., Y. Xu, J. L., J. Chromatography B, 2003; 785:65-72.
11. Hasan N, Chaiharn M, Khalid H, Jabbar A, Pharm Anal Acta 2013; 4(8):1000263.
12. Thippani R, Pothuraju NR, Ramisetti NR, Shaik S, Journal of Pharmaceutical Analysis, article in press.
13. Cheng X, Guo L, Li Z, Li L, Zhou T, Lu W, Journal of Chromatography B, 2013; 915-916:64-70.
14. Lin H, Gounder MK, Kong AT, Dipaola RS, Journal of Pharmaceutical and Biomedical Analysis, 2012; 66:371-375.
15. Ulu ST, Journal of Pharmaceutical and Biomedical Analysis, 43; 2007:1444-1451.
16. Liu M, Wang J, Wu X, Wang E, Baptista D, Journal of Pharmaceutical and Biomedical Analysis, 2014; 89: 34-41.
17. Cattel L, Airoldi M, Delprino L, Passera R, Milla P, Pedani F, Annals of Oncology 2006; 17 (5):142-147.
18. De Brabander-van Den Berg E M M, Meijer E W. Poly(propylene imine) SLNs: Large-Scale Synthesis by Hetereogeneously Catalyzed Hydrogenations. Angew. Chem. Int. Ed. Engl., 1993; 32:1308-1311.
19. Kumar P.V., Agashe H., Dutta T. Jain NK, Curr. Drug Deliv., 2007; 3:000-000
20. Kumar P.V., Agashe H., Dutta T. Jain NK, J. Drug Targeting, 2006; 14:546â€“556.
21. Caminade AM. Laurent R, Majoral JP,. Adv. Drug. Del. Rev., 2005; 57:2130-2146.
22. Indian Pharmacopoeia, Govt. of India, Ministry of Health and Family Welfare, New Delhi. 2007, I: 323.
23. Pasut G, Canal F, Via DL, Arpicco S, Veronese FM, Schiavon O, Journal of Controlled Release 2008; 127:239-248.
24. ICH-Q2B (2005) Guideline for Industry, Q2B Validation of Analytical Procedure: Methodology. International Conference on Harmonisation, Food and Drug Administration, U.S. Department of Health and Human Services.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).